FoxO1 signaling in B cell malignancies and its therapeutic targeting
FEBS Letters · 2025-10 · 599 (20) · 2911-2931
DOI: 10.1002/1873-3468.15057 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift FEBS Letters, online erschienen am 12.11.2024. Verfasst von Krystof Hlavac und 3 weiteren Autor:innen. Beteiligte Einrichtung: Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Signal Transduction, Forkhead Box Protein O1, B-Lymphocytes, Lymphoma, B-Cell. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine, Masaryk University, National Institute for Cancer Research, Ministry of Health of the Czech Republic.
Abstract (Originalsprache)
FoxO transcription factors (FoxO1, FoxO3a, FoxO4, FoxO6) are a highly evolutionary conserved subfamily of the ‘forkhead’ box proteins. They have traditionally been considered tumor suppressors, but FoxO1 also exhibits oncogenic properties. The complex nature of FoxO1 is illustrated by its various roles in B cell development and differentiation, immunoglobulin gene rearrangement and cell‐surface B cell receptor (BCR) structure, DNA damage control, cell cycle regulation, and germinal center reaction. FoxO1 is tightly regulated at a transcriptional (STAT3, HEB, EBF, FoxOs) and post‐transcriptional level (Akt, AMPK, CDK2, GSK3, IKKs, JNK, MAPK/Erk, SGK1, miRNA). In B cell malignancies, recurrent FoxO1 activating mutations (S22/T24) and aberrant nuclear export and activity have been described, underscoring the potential of its therapeutic inhibition. Here, we review FoxO1's roles across B cell and myeloid malignancies, namely acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and multiple myeloma (MM). We also discuss preclinical evidence for FoxO1 targeting by currently available inhibitors (AS1708727, AS1842856, cpd10).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Brno, Czech Republic.
ORCID-Profile: Marek Mraz
Förderung
- Faculty of Medicine, Masaryk University
- National Institute for Cancer Research
- Ministry of Health of the Czech Republic
- Lékařská fakulta, Masarykova univerzita
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Hlavac, K., Pavelkova, P., Ondrisova, L., & Mraz, M. (2025). FoxO1 signaling in B cell malignancies and its therapeutic targeting. FEBS Letters, 599(20), 2911-2931. https://doi.org/10.1002/1873-3468.15057
Vancouver
Hlavac K, Pavelkova P, Ondrisova L, Mraz M. FoxO1 signaling in B cell malignancies and its therapeutic targeting. FEBS Letters. 2025;599(20):2911-2931. doi:10.1002/1873-3468.15057
BibTeX
@article{Hlavac2025,
author = {Hlavac, Krystof and Pavelkova, Petra and Ondrisova, Laura and Mraz, Marek},
title = {FoxO1 signaling in B cell malignancies and its therapeutic targeting},
journal = {FEBS Letters},
year = {2025},
volume = {599},
number = {20},
pages = {2911--2931},
doi = {10.1002/1873-3468.15057}
}
EUVIMED